- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gilead Sciences Inc DRC (GILD34)
Track today's live Gilead Sciences DRC (GILD34) share price, performance and key data on this page with our current B3:GILD34 stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Gilead Sciences DRC share price on the B3 exchange. Use the dropdown to switch exchange for the GILD34 share price, head to our technical summary section, which provides analysis on Gilead Sciences DRC share price buy/sell indicators using real-time data (or discuss the Gilead Sciences DRC (GILD34) stock price today with other investors in the Gilead Sciences DRC BVMF share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current BVMF:GILD34 share price (ISIN: BRGILDBDR000) to enhance your trading decisions with our free investment tools and resources.
What Is the Gilead Sciences Inc DRC Share Price Today?
The Gilead Sciences DRC share price today is 63.78.
What Is the Stock Symbol for Gilead Sciences Inc DRC
The stock symbol (or 'ticker') for Gilead Sciences Inc is "GILD34."
What Stock Exchange Does Gilead Sciences Inc DRC Trade On?
Gilead Sciences Inc is listed and trades on the B3 stock exchange.
Is Gilead Sciences Inc DRC a Good Stock to Buy?
Determining whether Gilead Sciences DRC (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current BVMF:GILD34 share price (ISIN: BRGILDBDR000) to enhance your trading decisions with our free investment tools and resources.
What Is the Gilead Sciences Inc DRC Share Price Today?
The Gilead Sciences DRC share price today is 63.78.
What Is the Stock Symbol for Gilead Sciences Inc DRC
The stock symbol (or 'ticker') for Gilead Sciences Inc is "GILD34."
What Stock Exchange Does Gilead Sciences Inc DRC Trade On?
Gilead Sciences Inc is listed and trades on the B3 stock exchange.
Is Gilead Sciences Inc DRC a Good Stock to Buy?
Determining whether Gilead Sciences DRC (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
63.78
-0.24(-0.37%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
63.25
63.80
52 wk Range
48.33
65.49
GILD34 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
63.2563.80
52 wk Range
48.3365.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.47%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.47%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GILD34 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Biotechnology industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Earnings
Latest Release
04/08/2026
EPS / Forecast
-8.45 / --
Revenue / Forecast
7.8B / --
Compare GILD34 to Peers and Sector
Metrics to compare | GILD34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILD34PeersSector | |
|---|---|---|---|---|
P/E Ratio | −57.4x | −3.9x | −0.4x | |
PEG Ratio | 0.38 | 0.02 | 0.00 | |
Price/Book | 15.7x | 1.3x | 2.6x | |
Price / LTM Sales | 6.1x | 1.1x | 3.1x | |
Upside (Analyst Target) | - | 10.9% | 49.0% | |
Fair Value Upside | Unlock | −2.2% | 7.0% | Unlock |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Gilead Sciences DRC (B3: GILD34) Share Price Today?
The Gilead Sciences DRC stock price today is 63.78 BRL.
What Stock Exchange Does Gilead Sciences DRC (GILD34) Trade On?
Gilead Sciences DRC is listed and trades on the B3 Stock Exchange.
What Is the Ticker (Stock Symbol) for Gilead Sciences DRC?
The stock symbol (also called a 'ticker') for Gilead Sciences DRC is "GILD34."
Does Gilead Sciences DRC Pay Dividends? What’s The Current GILD34 Dividend Yield?
Yes, GILD34 Pays Dividends to its Shareholders. The current Gilead Sciences DRC dividend yield is 1.47%.
What Is the Current Gilead Sciences DRC Market Capitalisation?
As of today, Gilead Sciences DRC (B3: GILD34) market cap is 946.51B BRL.
What Is Gilead Sciences DRC's (GILD34) Earnings Per Share (TTM)?
The Gilead Sciences DRC EPS is currently -2.62 (Trailing Twelve Months).
Is GILD34 a Buy or Sell From a Technical Analyst Perspective?
Based on today's Gilead Sciences DRC moving averages and other technical indicators, the daily buy/sell signal for GILD34 stock is Strong Buy.
How Many Times Has Gilead Sciences DRC Stock Split?
Gilead Sciences DRC has split 1 times. (See the GILD34 stock split history page for full effective split date and price information.)
How Many Employees Does Gilead Sciences DRC Have?
Gilead Sciences DRC has 17000 employees, based on their latest Companies House report.
What is the current trading status of Gilead Sciences DRC (B3: GILD34)?
As of 02/09/2026, Gilead Sciences DRC (GILD34) is trading at a share price of 63.78 BRL, with a previous close of 64.02 BRL. The stock has fluctuated within a day range of 63.25 BRL to 63.80 BRL, while its 52-week range spans from 48.33 BRL to 65.49 BRL.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.